Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/is-the-patent-system-a-barrier-to-inclusive-prosperity-the-biomedical-FEsW0P0RVL
References (53)
-
(2018)
The Open Revolution: Rewriting the Rules of the Information Age -
(2015)
How Corporate Lobbyists Conquered American Democracy -
Sandy Thomas, M. Hopkins, M. Brady (2002)
Shares in the human genome—the future of patenting DNANature Biotechnology, 20
-
M. David (2017)
Sharing: Crime Against Capitalism -
S. Macdonald (2004)
When means become ends: considering the impact of patent strategy on innovationInf. Econ. Policy, 16
-
W. Nagan, J. Cartner, R. Munro (2016)
Human Rights and Dynamic Humanism -
M. David, Debora Halbert (2017)
Intellectual Property & Global PolicyGlobal Policy, 8
-
C. Macleod (1988)
Inventing the Industrial Revolution: List of tables and figure -
A. Abbott (2004)
Pressured staff ‘lose faith’ in patent qualityNature, 429
-
(2010)
Deconstructing the Patent Application Backlog -
(2012)
Research Division Federal Reserve Bank of St. Louis Working Paper Series The Case Against Patents -
J. Turner (1998)
The Nonmanufacturing Patent Owner: Toward a Theory of Efficient InfringementCalifornia Law Review, 86
-
J. DiMasi, R. Hansen, H. Grabowski (2003)
The price of innovation: new estimates of drug development costs.Journal of health economics, 22 2
-
(1988)
Inventing the Industrial Revolution: Acknowledgements -
J. Reichman (2009)
Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the OptionsThe Journal of Law, Medicine & Ethics, 37
-
Julian Clark (2011)
Do Patents and Intellectual Property Protection Hinder Biomedical Research? A Practical PerspectiveAustralian Economic Review, 44
-
J. Barton (2000)
Reforming the Patent SystemScience, 287
-
Stefano Barazza (2014)
Pay-for-Delay Agreements in the Pharmaceutical Sector: Towards a Coherent EU Approach?`European Journal of Risk Regulation, 5
-
W. Choi, Bruce Uyl, M. Hughes (2014)
Pay-For-Delay Practices in the Pharmaceutical Sector: Lundbeck, Actavis, and OthersJournal of European Competition Law & Practice, 5
-
M. Heller, R. Eisenberg (1998)
Can Patents Deter Innovation? The Anticommons in Biomedical ResearchIntellectual Property Law eJournal
-
S. Maurer, A. Rai, A. Sali (2004)
Finding Cures for Tropical Diseases: Is Open Source an Answer?PLoS Medicine, 1
-
(2004)
Pressured Staff ‘Lose Faith -
K. Blind, K. Cremers, Elisabeth Mueller (2009)
The Influence of Strategic Patenting on Companies' Patent PortfoliosIntellectual Property Law eJournal
-
R. Posner (2002)
The Law and Economics of Intellectual PropertyDaedalus
-
S. Chandrasekharan, Sapna Kumar, Cory Valley, A. Rai (2009)
Proprietary science, open science and the role of patent disclosure: the case of zinc-finger proteinsNature Biotechnology, 27
-
O. Granstrand, F. Tietze (2014)
IP strategies and policies for and against evergreening -
(2016)
Access to Medicine in the U.S.: A Study about How Heavily Lobbied Laws Impact the Ability of Americans to Access Medicine through Affordable Prescription Drugs and Effective Doctors -
R. Merges, R. Nelson (1990)
On the Complex Economics of Patent ScopeColumbia Law Review, 90
-
S. Torrisi, A. Gambardella, P. Giuri, D. Harhoff, Karin Hoisl, M. Mariani (2016)
Used, Blocking and Sleeping Patents: Empirical Evidence from a Large-Scale Inventor SurveyResearch Policy, 45
-
M. Boldrin, D. K. Levine (2013)
The Case Against Patents, 27
-
D. Light, R. Warburton (2011)
Demythologizing the high costs of pharmaceutical researchBioSocieties, 6
-
J. Stiglitz (2006)
Scrooge and intellectual property rights -
(2001)
Rewards versus Intellectual Property Rights -
E. Mayr (2002)
The biology of race and the concept of equalityDaedalus, 131
-
(2015)
Drug Goes from $13.50 a Tablet to $750, Overnight -
James Bessen, M. Meurer (2008)
Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk -
Laura Mancuso (2012)
Can Patents Deter Innovation -
(1997)
Need: A New System of Intellectual Property Rights -
R. Beall, J. Nickerson, W. Kaplan, A. Attaran (2016)
Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products?PLoS ONE, 11
-
A. Smith (1762‐3)
Lectures on Jurisprudence -
(2000)
Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) -
N. Thumm (2004)
Strategic Patenting in BiotechnologyTechnology Analysis & Strategic Management, 16
-
T. Caulfield, R. Cook-Deegan, Scott Kieff, John Walsh (2006)
Evidence and anecdotes: an analysis of human gene patenting controversiesNature Biotechnology, 24
-
J. Bentham (1843)
A Manual of Political Economy, 3
-
K. Blind, K. Blind, J. Edler, Rainer Frietsch, U. Schmoch (2006)
Motives to patent: Empirical evidence from GermanyResearch Policy, 35
-
R. Eisenberg, R. Nelson (2002)
Public vs. Proprietary Science: A Fruitful Tension?Academic Medicine, 77
-
S. Flynn, A. Hollis, Michael Palmedo (2009)
An Economic Justification for Open Access to Essential Medicine Patents in Developing CountriesThe Journal of Law, Medicine & Ethics, 37
-
C. Henry, J. Stiglitz (2010)
Intellectual Property, Dissemination of Innovation and Sustainable DevelopmentGlobal Policy, 1
-
Petra Koenig (2016)
Inventing The Industrial Revolution The English Patent System 1660 1800 -
J. Steinbruner, J. Lewis (2002)
The Unsettled Legacy of the Cold WarDaedalus, 131
-
Peter Neuhäusler (2012)
The use of patents and informal appropriation mechanisms—Differences between sectors and among companiesTechnovation, 32
-
G. Dwivedi, Sharanabasava Hallihosur, L. Rangan (2010)
Evergreening: A deceptive device in patent rightsTechnology in Society, 32
-
S. Bergel (2015)
Patentability of human genes: the conceptual differences between the industrialised and Latin American countriesJournal of Community Genetics, 6
- Publisher
- Wiley
- Copyright
- Copyright © 2020 University of Durham and John Wiley & Sons, Ltd
- ISSN
- 1758-5880
- eISSN
- 1758-5899
- DOI
- 10.1111/1758-5899.12730
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Global Policy – Wiley
Published: Feb 1, 2020